These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 19629074)

  • 1. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.
    Jänne PA; Gray N; Settleman J
    Nat Rev Drug Discov; 2009 Sep; 8(9):709-23. PubMed ID: 19629074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting cancer with small molecule kinase inhibitors.
    Zhang J; Yang PL; Gray NS
    Nat Rev Cancer; 2009 Jan; 9(1):28-39. PubMed ID: 19104514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibitors of protein kinases in cancer- how to overcome resistance.
    Griffith R; Brown MN; McCluskey A; Ashman LK
    Mini Rev Med Chem; 2006 Oct; 6(10):1101-10. PubMed ID: 17073710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
    Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
    Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule kinase inhibitors as anti-cancer therapeutics.
    Chahrour O; Cairns D; Omran Z
    Mini Rev Med Chem; 2012 May; 12(5):399-411. PubMed ID: 22303944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer.
    Essegian D; Khurana R; Stathias V; Schürer SC
    Cell Rep Med; 2020 Oct; 1(7):100128. PubMed ID: 33205077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.
    Heffron TP
    J Med Chem; 2016 Nov; 59(22):10030-10066. PubMed ID: 27414067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors.
    Krishnamurty R; Maly DJ
    ACS Chem Biol; 2010 Jan; 5(1):121-38. PubMed ID: 20044834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of Kinase-Directed Therapies--A Network Perspective on Response and Resistance.
    Murray BW; Miller N
    Mol Cancer Ther; 2015 Sep; 14(9):1975-84. PubMed ID: 26264276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
    Milik SN; Lasheen DS; Serya RAT; Abouzid KAM
    Eur J Med Chem; 2017 Dec; 142():131-151. PubMed ID: 28754471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.
    Bagrodia S; Smeal T; Abraham RT
    Pigment Cell Melanoma Res; 2012 Nov; 25(6):819-31. PubMed ID: 22883054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells.
    Cassinelli G; Zuco V; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
    Curr Med Chem; 2013; 20(15):1923-45. PubMed ID: 23410153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in selective small molecule ATP-targeting the serine/threonine kinase Akt/PKB.
    Wang P; Zhang L; Hao Q; Zhao G
    Mini Rev Med Chem; 2011 Nov; 11(13):1093-107. PubMed ID: 22353219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments and advances of FGFR as a potential target in cancer.
    Xue WJ; Li MT; Chen L; Sun LP; Li YY
    Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
    Parikh PK; Ghate MD
    Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrazine-based small molecule kinase inhibitors: clinical applications and patent review (2019-2023).
    Alsfouk A
    Future Med Chem; 2024; 16(18):1899-1921. PubMed ID: 39189138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic response of staurosporine scaffold-based inhibitors to drug-resistant cancer kinase mutations.
    He Y
    Arch Pharm (Weinheim); 2020 Jun; 353(6):e1900320. PubMed ID: 32285482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting cancer with kinase inhibitors.
    Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
    J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
    Smolewski P
    Anticancer Drugs; 2006 Jun; 17(5):487-94. PubMed ID: 16702804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.